ATHE ALTERITY THERAPEUTICS LTD IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1131343 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2018-06-30 (FY2018), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY2025*2025-06-30 | FY2024*2024-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 14.40M | 18.64M |
| SG&A expense | 5.48M | 4.76M |
| Interest expense | 6,188 | 7,217 |
| Pretax income | -12.08M | -19.08M |
| Income tax | 68,055 | 46,088 |
| Net income | -12.15M | -19.12M |
| EPS (basic) | -0.19 | -0.52 |
| EPS (diluted) | -0.19 | -0.52 |
| Weighted avg. shares (diluted) | 6.40B | 3.65B |
| Balance sheet | ||
| Cash & equivalents | 33.16M | 12.64M |
| Receivables | 3.94M | 4.04M |
| Current assets | 45.87M | 19.04M |
| PP&E, netmay include right-of-use assets (IFRS) | 3,848 | 32,154 |
| Total assets | 46.03M | 19.22M |
| Current liabilities | 3.53M | 5.37M |
| Total liabilities | 3.62M | 5.43M |
| Shareholders' equity | -225.89M | -214.16M |
| Cash flow statement | ||
| Operating cash flow | -11.45M | -12.61M |
| Capital expenditure | — | 5,722 |
| Free cash flow | — | -12.61M |
| Investing cash flow | -7.50M | -5,722 |
| Financing cash flow | 39.67M | 9.22M |
| Stock-based compensation | 979,920 | 881,950 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.